Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672053 | 0.77 | NFE2L2 (0.37) | NFE2L2APLNRAURKATTKAURKB | |
| SCHEMBL28279220 | 0.77 | NFE2L2 (0.34) | NFE2L2APLNRAURKATTKAURKB | |
| SCHEMBL1476027 | 0.77 | NFE2L2 (0.37) | NFE2L2APLNRAURKATTKAURKB | |
| SCHEMBL607884 | 0.74 | APLNR (0.40) | APLNRAURKATTKAURKBINCENP | |
| SCHEMBL873036 | 0.74 | HDAC8 (0.32) | — | |
| SCHEMBL32659903 | 0.74 | HDAC8 (0.32) | — | |
| SCHEMBL29060479 | 0.74 | NFE2L2 (0.33) | NFE2L2APLNR | |
| SCHEMBL3852166 | 0.72 | KDM4E (0.36) | NFE2L2APLNRMEN1KMT2A | |
| SCHEMBL896496 | 0.71 | HTT (0.33) | MITF | |
| SCHEMBL23623967 | 0.70 | CCR4 (0.39) | MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9184428-B2 | Non-aqueous electrolytes for lithium ion batteries | UCHICAGO ARGONNE LLC (US) | 2015-11-10 | — | — | US | claimed |
| US-9012096-B2 | Long life lithium batteries with stabilized electrodes | UCHICAGO ARGONNE, LLC (US) | 2015-04-21 | — | — | US | claimed |
| US-7851092-B2 | Redox shuttles for overcharge protection of lithium batteries | U CHICAGO ARGONNE LLC (US) | 2010-12-14 | — | — | US | claimed |
| WO-2006101779-A2 | NON-AQUEOUS ELECTROLYTES FOR LITHIUM ION BATTERIES | THE UNIVERSITY OF CHICAGO (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060210883-A1 | Non-aqueous electrolytes for lithium ion batteries | THE UNIVERSITY OF CHICAGO | 2006-09-21 | — | — | US | claimed |
| WO-2006094069-A2 | NOVEL REDOX SHUTTLES FOR OVERCHARGE PROTECTION OF LITHIUM BATTERIES | UCHICAGO ARGONNE, LLC (US) | 2006-09-08 | — | — | WO | claimed |
| US-20060199080-A1 | Novel redox shuttles for overcharge protection of lithium batteries | THE UNIVERSITY OF CHICAGO | 2006-09-07 | — | — | US | claimed |
| US-20060147809-A1 | Non-aqueous electrolyte of an alkali metal salt, a polar aprotic solvent, and an electrode stabilization additive comprising a linear, branched or cyclic hydrocarbon, other than a spirocyclic hydrocarbon, comprising at least one oxygen atom and at least one aryl, alkenyl or alkynyl group | THE UNIVERSITY OF CHICAGO | 2006-07-06 | — | — | US | claimed |
| US-12327844-B2 | Materials to improve the performance of lithium and sodium batteries | UCHICAGO ARGONNE, LLC (US) | 2025-06-10 | — | — | US | disclosed |
| EP-3656010-B1 | PHOSPHORUS-CONTAINING ELECTROLYTES | SIONIC ENERGY INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250079514-A1 | SILYL ENOLATES FOR USE IN LITHIUM BATTERY ELECTROLYTES | UCHICAGO ARGONNE, LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12155038-B2 | Modified ionic liquids containing bicyclophosphate moiety | Sionic Energy, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12021226-B2 | Cathode materials for secondary batteries | UCHICAGO ARGONNE, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3656009-B1 | MODIFIED IONIC LIQUIDS CONTAINING TRIAZINE | NOHMS TECH INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20070148545-A1 | Electrode materials and lithium battery systems | THE UNIVERSITY OF CHICAGO | 2007-06-28 | — | — | US | disclosed |
| WO-2006101779-A2 | NON-AQUEOUS ELECTROLYTES FOR LITHIUM ION BATTERIES | THE UNIVERSITY OF CHICAGO (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060210883-A1 | Non-aqueous electrolytes for lithium ion batteries | THE UNIVERSITY OF CHICAGO | 2006-09-21 | — | — | US | disclosed |
| WO-2006094069-A2 | NOVEL REDOX SHUTTLES FOR OVERCHARGE PROTECTION OF LITHIUM BATTERIES | UCHICAGO ARGONNE, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199080-A1 | Novel redox shuttles for overcharge protection of lithium batteries | THE UNIVERSITY OF CHICAGO | 2006-09-07 | — | — | US | disclosed |
| US-20060147809-A1 | Non-aqueous electrolyte of an alkali metal salt, a polar aprotic solvent, and an electrode stabilization additive comprising a linear, branched or cyclic hydrocarbon, other than a spirocyclic hydrocarbon, comprising at least one oxygen atom and at least one aryl, alkenyl or alkynyl group | THE UNIVERSITY OF CHICAGO | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250079514-A1 | SILYL ENOLATES FOR USE IN LITHIUM BATTERY ELECTROLYTES | SELENOI, SLC10A1, SLC9A3 | NFE2L2 1942/4885APLNR 4793/4885MITF 4640/4885 |
| US-12155038-B2 | Modified ionic liquids containing bicyclophosphate moiety | IPMK, PPIP5K2, OSGEP | NFE2L2 3878/4885APLNR 4139/4885MITF 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.